Royal Bank of Canada Analysts Give MorphoSys (MOR) a €57.00 Price Target

Royal Bank of Canada set a €57.00 ($70.37) price objective on MorphoSys (ETR:MOR) in a research note issued to investors on Wednesday morning. The firm currently has a sell rating on the stock.

Other analysts have also recently issued research reports about the company. Independent Research set a €93.00 ($114.81) target price on MorphoSys and gave the stock a buy rating in a research report on Tuesday, November 7th. JPMorgan Chase & Co. set a €85.00 ($104.94) target price on MorphoSys and gave the stock a buy rating in a research report on Wednesday, November 8th. Berenberg Bank set a €85.00 ($104.94) target price on MorphoSys and gave the stock a buy rating in a research report on Tuesday, November 7th. Deutsche Bank set a €90.00 ($111.11) target price on MorphoSys and gave the stock a buy rating in a research report on Wednesday, November 8th. Finally, Goldman Sachs Group set a €72.00 ($88.89) target price on MorphoSys and gave the stock a neutral rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of €79.10 ($97.65).

Shares of MorphoSys (ETR MOR) opened at €75.55 ($93.27) on Wednesday. MorphoSys has a 52-week low of €48.92 ($60.40) and a 52-week high of €87.35 ($107.84). The company has a market capitalization of $2,220.00 and a PE ratio of -25.61.

TRADEMARK VIOLATION WARNING: “Royal Bank of Canada Analysts Give MorphoSys (MOR) a €57.00 Price Target” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/royal-bank-of-canada-analysts-give-morphosys-mor-a-57-00-price-target.html.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply